<DOC>
	<DOCNO>NCT02310048</DOCNO>
	<brief_summary>The purpose study assess comparative oral bioavailability Formulation B versus Formulation A MT-1303 .</brief_summary>
	<brief_title>Comparative Oral Bioavailability Study MT-1303</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Caucasian male age 18 55 year Screening . Healthy free clinically significant illness disease determine medical history , physical examination , laboratory , test Screening Day 1 . A body weight â‰¥60 kilogram ( kg ) BMI range 18 30 kg/m2 Screening Day 1 . Presence history severe adverse reaction allergy medicinal product relevant excipient clinical significance . Participated three clinical study new chemical entity previous year participate clinical study IMP within 12 week five halflives IMP administration IMP clinical study . Clinically relevant abnormal medical history , physical finding , laboratory value Screening Day 1 could interfere objective study safety subject , judge Investigator . Previous medical history tuberculosis opinion Investigator recurrent medical history cold sore , pharyngitis , urinary tract infection , diarrhoea/dysentery , chest infection , fungal infection . Subjects receive prescribed systemic topical medication within 14 day prior administration IMP ( Day 1 ) unless , opinion Investigator Sponsor , medication interfere study procedure compromise safety . Slow release medicinal formulation consider still active within 14 day prior first dose administration also exclude unless , opinion Investigator Sponsor , medication interfere study procedure compromise safety .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>